Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
KamadaXTAE:KMDA -0.82%84 Dividend Yield % is 3.53% as of Aug. 05, 2026, which is 6% above its 10-year median of 3.33. GuruFocus rates XTAE:KMDA with a GF Score™ of 84/100 and a GF Value™ of ₪25.14 (Modestly Undervalued). Among 514 Drug Manufacturers companies, Kamada ranks better than 75.49% on this metric.
As of today (2026-08-05), the Trailing Annual Dividend Yield of Kamada is 3.53%.
The historical rank and industry rank for Kamada's Dividend Yield % or its related term are showing as below:
XTAE:KMDA'
s Dividend Yield % Range Over the Past 10 Years
Min: 2.85 Med: 3.33 Max: 3.53
Current: 3.53
During the past 13 years, the highest Dividend Yield of Kamada was 3.53%. The lowest was 2.85%. And the median was 3.33%.
XTAE:KMDA's Dividend Yield % is ranked better than 75.49% of 514
companies
in the Drug Manufacturers industry
Industry Median: 1.985
vs XTAE:KMDA: 3.53
Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.
Dividends may also qualify a lower tax rate for investors.
In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
The historical data trend for Kamada's Dividend Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XTAE:KMDA vs ZTS, UTHR, VTRS: Dividend Yield % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Kamada's Dividend Yield %, along with its competitors' market caps and Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kamada Dividend Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Kamada's Dividend Yield % distribution charts can be found below:
* The bar in red indicates where Kamada's Dividend Yield % falls into.
Dividend Yield measures how much a company pays out in dividends each year relative to its share price.
Kamada Recent Full-Year* Dividend History
Amount
Ex-date
Record Date
Pay Date
Type
Frequency
Forex Rate
ILS 0.770000
2026-03-23
2026-03-23
2026-04-07
Cash Dividend
annually
ILS:ILS 1.000000
* GuruFocus has an internal rule that if the most recent dividend payment frequency is at least 4 times a year, then the full year will be calculated according to the frequency of payment or the one-year time frame, whichever is stricter.
* GuruFocus converts dividend currency to local traded share price currency in order to calculate dividend yield. Please refer to the last column "Forex Rate" in the above table.
Kamada's Trailing Annual Dividend Yield (%) for Today is calculated as
Trailing Annual Dividend Yield
=
Most Recent Full Year Dividend
/
Current Share Price
=
0.77
/
21.80
=
3.53 %
Current Share Price is ₪21.80. Kamada's Dividends per Share for the trailing twelve months (TTM) ended in Today is ₪0.77.
Kamada's Forward Annual Dividend Yield (%) for Today is calculated as
Forward Annual Dividend Yield
=
Forward Full Year Dividend
/
Current Share Price
=
0.77
/
21.80
=
3.53 %
Current Share Price is ₪21.80. Kamada's Dividends per Share for the forward twelve months is calculated as ₪0.77 * 1 = ₪0.77.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kamada (XTAE:KMDA) has a Dividend Yield % of 3.53% as of Aug. 05, 2026. Dividend yield is the ratio of company dividends to the share price. View historical data on Kamada and its competitors. This is near median its historical median of 3.33. Over the past decade, Kamada's Dividend Yield % has ranged from 2.85 to 3.53. According to the industry distribution chart, Kamada ranks #126 out of 514 companies in the Drug Manufacturers industry, placing it in the top 24.5%.
Is Kamada's Dividend Yield % too high?
Kamada's current Dividend Yield % of 3.53% is near median its 10-year median of 3.33. Over the past 10 years, this metric has ranged from a low of 2.85 to a high of 3.53. The Drug Manufacturers industry median Dividend Yield % is 1.99. Kamada's value of 3.53% is 77.8% above this industry median. Based on the distribution chart, Kamada ranks #126 out of 514 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Kamada has a GF Score™ of 84/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Kamada's Dividend Yield % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Kamada ranks #126 out of 514 companies for Dividend Yield %. This places Kamada in the top 25% of its industry — outperforming the majority of peers. The industry median Dividend Yield % is 1.99. Kamada's value of 3.53% is 77.8% above this benchmark. Historically, Kamada's own Dividend Yield % has ranged from 2.85 to 3.53 over the past decade. While the company's 10-year median is 3.33 vs. the industry median of 1.99, Kamada has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Dividend Yield % for a Drug Manufacturers company?
The median Dividend Yield % among Drug Manufacturers companies is 1.99, based on 514 companies in the industry. Companies in the top quartile (top 25%) have a Dividend Yield % significantly above this median, while those in the bottom quartile fall well below. However, Dividend Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Kamada's current Dividend Yield % of 3.53% is 77.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Dividend Yield % mean?
A high Dividend Yield % can signal that a stock is expensive relative to its fundamentals. Dividend yield is the ratio of company dividends to the share price. View historical data on Kamada and its competitors. For the Drug Manufacturers industry, the median Dividend Yield % is 1.99 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kamada's current Dividend Yield % is 3.53%, which is near median its own 10-year median of 3.33. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kamada stock overvalued right now?
Based on GuruFocus' analysis, Kamada (XTAE:KMDA) is currently considered Modestly Undervalued. The stock's GF Value™ is ₪25.14, compared to a current price of ₪21.80 — trading 13.3% below its estimated fair value. The current Dividend Yield % is 3.53%, which is near median its 10-year median of 3.33 and 77.8% above the Drug Manufacturers industry median of 1.99. Kamada's overall GF Score™ is 84/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Dividend Yield % calculated?
Dividend Yield % is calculated from a company's financial statements. For Kamada (XTAE:KMDA), the current Dividend Yield % is 3.53% as of Aug. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Kamada (XTAE:KMDA) Overvalued in 2026?
Based on GuruFocus' analysis, Kamada stock appears to be undervalued.
The current stock price of ₪21.80 is trading 13.3% below its estimated GF Value™ of ₪25.14.
GuruFocus considers Kamada to be Modestly Undervalued.
Key valuation signals for XTAE:KMDA:
Dividend Yield %: 3.53% (near median its 10-year median of 3.33)
GF Value™: ₪25.14 vs. price of ₪21.80 (13.3% below fair value)
Industry Position: 77.8% above the Drug Manufacturers median (#126 of 514)
No single metric tells the full story. See the XTAE:KMDA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, the Proprietary Products segment and the Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.
84GF Score
Get the complete analysis for XTAE:KMDA
Dividend Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XTAE:KMDA has been successfully added to your 
